MDMA approved by FDA for Phase 3 Clinical Trials to treat PTSD

Research into the use of psilocybin, ketamine, LSD, and MDMA to treat mental health conditions has gathered significant steam in the past few years. Positive outcomes have been reported repeatedly, especially when administered in microdoses under the care of a psychologist. MDMA is noted as an intense empathogen, removing psychological barriers and allowing for open and vulnerable work with a therapist. The story cites a 59% success rate upon initial administering of the chemical in a clinical setting to achieve significant treatment breakthroughs. However, FDA restrictions have limited studies of these controlled substances, just as medical research into the benefits of cannabis have been.
The FDA, now, has approved MDMA for the final phase of clinical trials, putting the chemical on pace to be legalized, clinically, in early 2017.


Philipps, Dave. (2016). "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients". New York Times. Web. 11/28/2016. http://www.nytimes.com/2016/11/29/us/ptsd-mdma-ecstasy.html